Therapies needed for posttraumatic inflammation and osteoarthritis prevention |
Readily identified population at high risk for osteoarthritis |
Pathways and targets identified |
Several clinical-stage therapeutic candidates |
Therapeutic window immediately following injury |
Long latency period until overt structural change |
Clinical trials for osteoarthritis prevention depend on surrogate markers |